AbbVie Inc  

(Public, NYSE:ABBV)   Watch this stock  
Find more results for abbvie
61.43
+0.57 (0.94%)
Real-time:   10:08AM EST
NYSE real-time data - Disclaimer
Currency in USD
Range 60.33 - 61.54
52 week 50.71 - 68.12
Open 60.76
Vol / Avg. 508,483.00/9.42M
Mkt cap 102.23B
P/E 16.52
Div/yield 0.64/4.17
EPS 3.72
Shares 1.63B
Beta 1.59
Inst. own 68%
Jan 27, 2017
Q4 2016 AbbVie Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 17, 2016
AbbVie Inc at Jefferies Healthcare Conference
Nov 8, 2016
AbbVie Inc at Credit Suisse Healthcare Conference
Oct 28, 2016
Q3 2016 AbbVie Inc Earnings Release
Oct 28, 2016
Q3 2016 AbbVie Inc Earnings Call - Webcast
Sep 14, 2016
AbbVie Inc at Morgan Stanley Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 24.84% 22.50%
Operating margin 36.71% 32.97%
EBITD margin - 38.09%
Return on average assets 9.58% 12.77%
Return on average equity 105.86% 180.90%
Employees 28,000 -
CDP Score - 89 D

Address

1 N Waukegan Rd
NORTH CHICAGO, IL 60064-1802
United States - Map
+1-847-9327900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women's health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.

Officers and directors

Richard A. Gonzalez Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
William J. Chase Executive Vice President, Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Michael Severino M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Laura J. Schumacher Executive Vice President, External Affairs, General Counsel and Corporate Secretary
Age: 52
Bio & Compensation  - Reuters
Carlos Alban Executive Vice President - Commercial Operations
Age: 53
Bio & Compensation  - Reuters
Henry O. Gosebruch Executive Vice President, Chief Strategy Officer
Age: 43
Bio & Compensation  - Reuters
Timothy J. Richmond Senior Vice President - Human Resources
Age: 49
Bio & Compensation  - Reuters
Azita Saleki-Gerhardt Ph.D. Senior Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Thomas A. Hurwich Vice President, Controller
Age: 55
Bio & Compensation  - Reuters
Robert J. Alpern M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters